| Bioactivity | Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia[1]. |
| Target | CD19. |
| Name | Denintuzumab |
| CAS | 1630074-14-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Farhadfar N, et al. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016 Oct;49:13-21. |